Conference
Pharmacokinetic (PK) analysis of a phase I trial investigating continuous treatment with the angiokinase inhibitor BIBF 1120 combined with pemetrexed in previously treated patients with non-small cell lung cancer (NSCLC)
Authors
Hanna NH; Zhao Y; Kaiser R; Stopfer P; Gyorffy S; Ellis PM
Volume
26
Pagination
pp. 14511-14511
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2008
DOI
10.1200/jco.2008.26.15_suppl.14511
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X